(Q41839207)

English

Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor

scientific article published on 13 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor (English)

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

object named as

Diane Ramsden

7

0 references

author name string

Lin-Zhi Chen

1

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

John P Sabo

2

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Elsy Philip

3

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Lois Rowland

4

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Yan Mao

5

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Bachir Latli

6

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Debra A Mandarino

8

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Rucha S Sane

9

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

language of work or name

0 references

publication date

13 October 2014

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

59

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

1

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

25-37

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C virus NS3/4 protease inhibitor, in healthy male subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

In vitro methods to support transporter evaluation in drug discovery and development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Telaprevir for retreatment of HCV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Membrane transporters in drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

In vitro-in vivo correlation of hepatobiliary drug clearance in humans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Methods to evaluate biliary excretion of drugs in humans: an updated review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

6 June 2018

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

18 August 2018

Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

18 August 2018

The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potentia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

18 August 2018

Isolation of a cinnamic acid-metabolizing Clostridium glycolicum strain from oil mill wastewaters and emendation of the species description

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291358

18 August 2018

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting

1 reference

https://pubmed.ncbi.nlm.nih.gov/25313217

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.03861-14

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41839207&oldid=1928695813"